Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2012

Open Access 01-12-2012 | Primary research

Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study

Authors: Naohisa Uchimura, Atsushi Kamijo, Takao Takase

Published in: Annals of General Psychiatry | Issue 1/2012

Login to get access

Abstract

Background

The primary objective of this study was to evaluate long-term (24-week) safety of eszopiclone in elderly and nonelderly Japanese patients with chronic insomnia. The secondary objectives were to evaluate short-term (4-week) efficacy and to assess for rebound insomnia or dependence after long-term treatment.

Methods

Patients (n = 164 elderly; n = 161 nonelderly), with or without psychiatric comorbidities, were randomized to receive low-dose (1 mg, elderly; 2 mg, nonelderly) or high-dose (2 mg, elderly; 3 mg, nonelderly) eszopiclone. The safety evaluation included adverse events, vital signs, clinical laboratory parameters, and electrocardiogram. Efficacy was assessed using patient reports of sleep latency (SL), total sleep time (TST), wake time after sleep onset (WASO), number of awakenings (NA), quality of sleep, depth of sleep, daytime sleepiness, daytime ability to function, and the 36-item Short Form (SF-36) Health Survey.

Results

The rate of adverse events was 81.5% in the 1-mg elderly group, 79.5% in the 2-mg elderly group, 82.1% in the 2-mg nonelderly group, and 87.0% in the 3-mg nonelderly group. Dysgeusia was the most common adverse event and was dose-related. Of 12 serious adverse events, none were considered by the investigator to be related to study medication. No rebound insomnia was observed. Eszopiclone significantly improved SL, TST, WASO, NA, and daytime sleepiness and function from baseline to Week 4, irrespective of age and psychiatric comorbidity. Improvements were also observed in SF-36 Mental Health Component scores in elderly and nonelderly patients with psychiatric comorbidities.

Conclusions

Irrespective of age, eszopiclone appeared safe as administered in this study for 24 weeks. Eszopiclone improved sleep variables in insomnia patients with and without psychiatric disorders and health-related quality of life in those with psychiatric disorders.

Trial registration

ClinicalTrials.gov #NCT00770692; http://​clinicaltrials.​gov/​ct2/​show/​NCT00770692.
Appendix
Available only for authorised users
Literature
1.
2.
State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements. 2005, 22: 1-30.
3.
Doi Y: Epidemiologic research on insomnia in the general Japanese populations. Nihon Rinsho. 2009, 67: 1463-1467.PubMed
4.
Neubauer DN: The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med. 2007, 3 (5 Suppl): S11-S15.PubMedCentralPubMed
5.
Hartikainen S, Lönnroos E, Louhivuori K: Medication as a risk factor for falls: Critical systematic review. J Gerontol A Biol Sci Med Sci. 2007, 62: 1172-1181. 10.1093/gerona/62.10.1172.CrossRefPubMed
6.
7.
Nutt DJ, Stahl SM: Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010, 24: 1601-1612. 10.1177/0269881109106927.CrossRefPubMed
8.
Lunesta® (eszopiclone) tablets 1 mg, 2 mg, 3 mg: US prescribing information. . 2010, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA
9.
Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T: Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004, 20: 1979-1991. 10.1185/174234304X15174.CrossRefPubMed
10.
Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T: Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003, 26: 793-799.PubMed
11.
Erman MK, Zammit G, Rubens R, Schaefer K, Wessel T, Amato D, Caron J, Walsh JK: A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med. 2008, 4: 229-234.PubMedCentralPubMed
12.
McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK: A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006, 22: 1633-1642. 10.1185/030079906X112741.CrossRefPubMed
13.
Scharf M, Erman M, Rosenberg R, Seiden D, McCall V, Amato D, Wessel TC: A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005, 28: 720-727.PubMed
14.
Foley D, Ancoli-Israel S, Britz P, Walsh J: Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res. 2004, 56: 497-502. 10.1016/j.jpsychores.2004.02.010.CrossRefPubMed
15.
Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T: A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010, 33: 225-234.PubMedCentralPubMed
16.
Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T: Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007, 30: 959-968.PubMedCentralPubMed
17.
Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA: An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005, 6: 487-495. 10.1016/j.sleep.2005.06.004.CrossRefPubMed
18.
McCall WV, Blocker JN, D’Agostino R, Kimball J, Boggs N, Lasater B, Haskett R, Krystal A, McDonald WM, Rosenquist PB: Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med. 2010, 6: 322-329.PubMedCentralPubMed
19.
Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T: Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006, 59: 1052-1060. 10.1016/j.biopsych.2006.01.016.CrossRefPubMed
20.
Pollack M, Kinrys G, Krystal A, McCall WV, Roth R, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R: Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008, 65: 551-562. 10.1001/archpsyc.65.5.551.CrossRefPubMed
21.
Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). 2000, American Psychiatric Press, Inc., Washington, DC
22.
Kurihara M, Jimbo M, Hirose T, Asano J, Endo S, Fujiya Y, Hada H, Haga M, Hasue I, Higuchi T, Karasumi H, Motomura H, Naito T, Nakamura R, Nakauchi M, Narita S, Noguchi T, Oyama K, Okada M, Okazaki Y, Sasaki K, Takahashi K, Takei H, Takeyama K, Watanabe J: Double-blind comparison of clinical effects of ID 540 (fludiazepam) diazepam and placebo on psychoneurotic patients and a tentative draft of dependency questionnaire [Japanese]. Rinsho Hyoka (Clinical Evaluation). 1977, 5: 341-368.
23.
Ohayon MM, Roth T: Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003, 37: 9-15. 10.1016/S0022-3956(02)00052-3.CrossRefPubMed
24.
Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC: Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biol Psychiatry. 2006, 60: 1364-1371. 10.1016/j.biopsych.2006.05.039.PubMedCentralCrossRefPubMed
25.
Neckelmann D, Mykletun A, Dahl AA: Chronic insomnia as a risk factor for developing anxiety and depression. Sleep. 2007, 30: 873-880.PubMedCentralPubMed
26.
Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rössler W: Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep. 2008, 31: 473-480.PubMedCentralPubMed
Metadata
Title
Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study
Authors
Naohisa Uchimura
Atsushi Kamijo
Takao Takase
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2012
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-11-15

Other articles of this Issue 1/2012

Annals of General Psychiatry 1/2012 Go to the issue

Case report

Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally

Primary research

Development of the Global Disability Scale (Glo.Di.S): preliminary results

Primary research

Effect of age and disease on bone mass in Japanese patients with schizophrenia

Primary research

Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study

Primary research

Clinical presentations of substance abuse in bipolar heroin addicts at time of treatment entry

Primary research

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece